Company Website:
http://www.ignyta.com
SAN DIEGO -- (Business Wire)
Ignyta, Inc. (Nasdaq: RXDX), a precision oncology
biotechnology company, today announced that it has been added to the
Russell 2000®, Russell 3000® and Russell Global Indexes as part of
Russell Investments' annual reconstitution that took place after market
close on June 26, 2015. The stock also was added systematically to the
appropriate growth and value indexes.
Russell indexes are widely used by investment managers and institutional
investors for index funds and as benchmarks for active investment
strategies. Approximately $5.7 trillion in assets are benchmarked to the
Russell’s U.S. indexes. Russell Indexes are part of FTSE Russell, a
leading global index provider.
About Ignyta, Inc.
Ignyta, Inc., located in San Diego, California, is a precision oncology
biotechnology company pursuing an integrated therapeutic (Rx) and
companion diagnostic (Dx) strategy for treating cancer patients. The
company’s goal with this Rx/Dx approach is to discover, develop and
commercialize new drugs that target activated cancer genes and pathways
for the customized treatment of cancer, as well as novel
chemotherapeutics that can potentially provide additional benefit to
cancer patients. It aims to achieve this goal by pairing its product
candidates with biomarker-based companion diagnostics that are designed
to identify, at the molecular level, the patients who are most likely to
benefit from the precisely targeted drugs the company develops. For more
information, please visit: www.ignyta.com.
Forward-Looking Statements
This press release contains forward-looking statements as that term is
defined in Section 27A of the Securities Act of 1933 and Section 21E of
the Securities Exchange Act of 1934. Statements in this press release
that are not purely historical are forward-looking statements. Such
forward-looking statements include, among other things, references to
the inclusion of Ignyta’s shares in the Russell 2000® Index. Actual
results could differ from those projected in any forward-looking
statements due to numerous factors. Such factors include, among others,
the inherent uncertainties associated with developing new products or
technologies and operating as a development stage company; Ignyta’s
ability to raise any additional funding it will need to continue to
pursue its business and product development plans; Ignyta’s ability to
obtain and maintain intellectual property protection for its product
candidates; the loss of key scientific or management personnel;
competition in the industry in which Ignyta operates; and market
conditions. These forward-looking statements are made as of the date of
this press release, and Ignyta assumes no obligation to update the
forward-looking statements, or to update the reasons why actual results
could differ from those projected in the forward-looking statements.
Investors should consult all of the information set forth herein and
should also refer to the risk factor disclosure set forth in the reports
and other documents the company files with the SEC available at www.sec.gov,
including without limitation Ignyta’s Annual Report on Form 10-K for the
year ended December 31, 2014 and subsequent Quarterly Reports on Form
10-Q.
View source version on businesswire.com: http://www.businesswire.com/news/home/20150629006385/en/
Contacts:
Ignyta, Inc.
Jacob Chacko, M.D.
CFO
858-255-5959
jc@ignyta.com
Source: Ignyta, Inc.
© 2024 Canjex Publishing Ltd. All rights reserved.